Investigational drug · Phase 3
C2407
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dyslipidemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 3, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "C2407"
First trial start
2025
Apr 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "C2407", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dyslipidemia
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "C2407" as an intervention, largest first.
- Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With DyslipidemiaPivotal-lookingCompleted
JW PharmaceuticalIndustry
NCT06955104 · 145 participants · Start Apr 3, 2025 · Primary completion Jul 30, 2025
Drug: JW0108 + C2407; JW0108 + C2407 placebo · For: Dyslipidemia
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Three patients with glycogen storage disease type II and the mutational spectrum of GAA in Korean patients.
Park HD, Lee DH, Choi TY, et al. · Ann Clin Lab Sci 2013
Also in development for Dyslipidemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.